FDA clears ZORYVE cream for children 2+

Unbranded medicated skin cream tube in pediatric dermatology setting after FDA clearance for children 2+ (ZORYVE)

Key Points

01FDA approves ZORYVE cream 0.3% for plaque psoriasis in children from age 2
02Expanded indication covers intertriginous areas and use anywhere on the body
03Label extension backed by a 4‑week MUSE study and long‑term open‑label data
04ZORYVE cream 0.3% is the first topical PDE4 inhibitor for psoriasis in children under 6

FDA expands ZORYVE indication to younger children

On June 29, 2026, the U.S. Food and Drug Administration approved a supplemental New Drug Application for Arcutis Biotherapeutics’ ZORYVE (roflumilast) cream 0.3%. The decision expands the product’s indication for the topical treatment of plaque psoriasis, including intertriginous areas, to pediatric patients as young as 2 years old.

With this action, ZORYVE cream 0.3% can now be used to treat plaque psoriasis in a broader pediatric population, extending below age 6. The approval centers on both disease control in typical plaque areas and involvement of intertriginous regions, which are often challenging to manage.

Product profile and dosing characteristics

ZORYVE cream 0.3% is described as a once‑daily, steroid‑free topical formulation. It is indicated as suitable for use anywhere on the body, including sensitive areas, and the labeling specifies no restrictions on duration of use.

These characteristics distinguish the product among topical options for plaque psoriasis. The absence of steroids and flexibility on application sites and duration may be relevant for long‑term management, especially in young children who may require ongoing therapy.

Clinical studies supporting pediatric approval

The pediatric label expansion is supported by a 4‑week Maximal Usage Systemic Exposure (MUSE) study, designated ARQ‑151‑216, conducted in children aged 2–5 years. This study evaluated systemic exposure under conditions of maximal topical use in this age group.

In addition, long‑term safety and efficacy data from an open‑label extension study, ARQ‑151‑306, contributed supportive evidence. The extension followed patients for up to 24 weeks, providing further information on the cream’s performance over an extended period in pediatric plaque psoriasis.

Mechanism and positioning in pediatric care

Reporting notes that ZORYVE cream 0.3% is the first and only topical phosphodiesterase‑4 (PDE4) inhibitor indicated for plaque psoriasis in children under 6 years of age. This places the product in a distinct mechanistic category within pediatric topical psoriasis treatments.

By offering a PDE4‑targeted topical option for very young patients, the approval broadens the range of mechanisms available for plaque psoriasis management in early childhood, alongside existing non‑PDE4 therapies.

Safety profile and adverse reactions

In use for plaque psoriasis, commonly reported adverse reactions with ZORYVE cream 0.3% include diarrhea, headache, insomnia and nausea. These reactions occurred at or above a 1% frequency in the data cited.

The safety findings from the MUSE study and the long‑term open‑label extension informed the benefit‑risk assessment for the new pediatric indication. The resulting label provides clinicians with information on both efficacy and tolerability in children as young as 2.

Key Takeaways

01The FDA’s June 29, 2026 decision significantly broadens ZORYVE’s reach by opening use in plaque psoriasis down to age 2, including intertriginous disease.
02ZORYVE’s once‑daily, steroid‑free profile with no duration limits may be particularly suited to chronic management needs in young children with psoriasis.
03Clinical evidence from both short‑term maximal‑use testing and longer open‑label follow‑up underpins the pediatric approval, supporting sustained use.
04As the first topical PDE4 inhibitor approved for plaque psoriasis in children under 6, ZORYVE establishes a new mechanistic option in early‑age psoriasis care.

References